Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?

NCT ID NCT00936858

Completed Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This phase II trial is testing an oral drug called RAD001 (everolimus) in people with advanced thyroid cancer that no longer responds to radioactive iodine treatment. The drug works by blocking a key growth pathway (mTOR) in cancer cells. The study aims to see if RAD001 can slow cancer progression and shrink tumors, potentially offering a new treatment option for this hard-to-treat condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RAD001 (everolimus), an oral drug that blocks the mTOR pathway to potentially slow cancer growth
What this could lead to: If this trial succeeds, it could offer a new treatment option for people with thyroid cancer that has stopped responding to radioactive iodine, potentially slowing disease progression.
What could go wrong: This is a phase II trial with a small number of participants, so results may not be conclusive. The drug may not be effective for all types of thyroid cancer and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID CANCER

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mt. Sinai Medical Center

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.